Nuo Therapeutics, Inc. (AURX)
USD 1.35
(-1.46%)
USD 1.35
(-1.46%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.17 Million USD | -4.83% |
| 2022 | -3.02 Million USD | -3236.6% |
| 2021 | -90.67 Thousand USD | 34.89% |
| 2020 | -139.26 Thousand USD | 90.17% |
| 2019 | -1.41 Million USD | 8.14% |
| 2018 | -1.54 Million USD | 89.71% |
| 2017 | -14.97 Million USD | -166.64% |
| 2016 | 22.47 Million USD | 142.57% |
| 2015 | -52.8 Million USD | -179.66% |
| 2014 | -18.88 Million USD | 6.74% |
| 2013 | -20.24 Million USD | -2.27% |
| 2012 | -19.79 Million USD | -463.96% |
| 2011 | -3.51 Million USD | 48.5% |
| 2010 | -6.81 Million USD | -98.24% |
| 2009 | -3.43 Million USD | 55.11% |
| 2008 | -7.66 Million USD | -52.06% |
| 2007 | -5.03 Million USD | -122.62% |
| 2006 | -2.26 Million USD | 65.2% |
| 2005 | -6.5 Million USD | 20.1% |
| 2004 | -8.13 Million USD | -97.32% |
| 2003 | -4.12 Million USD | -104.51% |
| 2002 | -2.01 Million USD | 90.5% |
| 2001 | -21.22 Million USD | 36.17% |
| 2000 | -33.25 Million USD | -437.24% |
| 1999 | -6.19 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -708.78 Thousand USD | -8.52% |
| 2024 Q2 | -540.09 Thousand USD | 23.8% |
| 2023 FY | -3.17 Million USD | -4.83% |
| 2023 Q2 | -871.88 Thousand USD | -1.75% |
| 2023 Q1 | -856.87 Thousand USD | 10.35% |
| 2023 Q3 | -790.64 Thousand USD | 9.32% |
| 2023 Q4 | -653.15 Thousand USD | 17.39% |
| 2022 Q1 | -228.94 Thousand USD | -219.52% |
| 2022 FY | -3.02 Million USD | -3236.6% |
| 2022 Q4 | -955.84 Thousand USD | -4.61% |
| 2022 Q3 | -913.71 Thousand USD | 1.15% |
| 2022 Q2 | -924.37 Thousand USD | -303.76% |
| 2021 Q2 | -6546.00 USD | -14.42% |
| 2021 Q1 | -5721.00 USD | 97.55% |
| 2021 Q4 | -71.65 Thousand USD | -961.35% |
| 2021 Q3 | -6751.00 USD | -3.13% |
| 2021 FY | -90.67 Thousand USD | 34.89% |
| 2020 FY | -139.26 Thousand USD | 90.17% |
| 2020 Q3 | -15.47 Thousand USD | 0.0% |
| 2020 Q4 | -233.85 Thousand USD | -1410.81% |
| 2019 FY | -1.41 Million USD | 8.14% |
| 2019 Q2 | -480.28 Thousand USD | 29.36% |
| 2019 Q3 | -92.62 Thousand USD | 80.72% |
| 2019 Q4 | 57.92 Thousand USD | 162.54% |
| 2019 Q1 | -679.9 Thousand USD | -284.53% |
| 2018 Q4 | 368.46 Thousand USD | 156.7% |
| 2018 FY | -1.54 Million USD | 89.71% |
| 2018 Q1 | -670.24 Thousand USD | 91.62% |
| 2018 Q3 | -649.87 Thousand USD | -10.12% |
| 2018 Q2 | -590.16 Thousand USD | 11.95% |
| 2017 Q3 | -1.37 Million USD | 64.8% |
| 2017 FY | -14.97 Million USD | -166.64% |
| 2017 Q1 | -1.69 Million USD | 31.86% |
| 2017 Q2 | -3.91 Million USD | -131.13% |
| 2017 Q4 | -7.99 Million USD | -480.81% |
| 2016 Q3 | -1.91 Million USD | -107.13% |
| 2016 Q1 | -4.87 Million USD | 88.46% |
| 2016 Q2 | 26.87 Million USD | 651.85% |
| 2016 FY | 22.47 Million USD | 142.57% |
| 2016 Q4 | -2.48 Million USD | -29.61% |
| 2015 FY | -52.8 Million USD | -179.66% |
| 2015 Q4 | -42.21 Million USD | -205.27% |
| 2015 Q3 | -13.82 Million USD | -1489.1% |
| 2015 Q2 | -870.23 Thousand USD | -121.19% |
| 2015 Q1 | 4.1 Million USD | 43.81% |
| 2014 Q2 | -11.32 Million USD | -100.97% |
| 2014 Q3 | -4.78 Million USD | 57.73% |
| 2014 Q4 | 2.85 Million USD | 159.68% |
| 2014 FY | -18.88 Million USD | 6.74% |
| 2014 Q1 | -5.63 Million USD | -15.0% |
| 2013 Q2 | -5.03 Million USD | 5.66% |
| 2013 Q4 | -4.89 Million USD | 1.55% |
| 2013 FY | -20.24 Million USD | -2.27% |
| 2013 Q1 | -5.33 Million USD | -39.25% |
| 2013 Q3 | -4.97 Million USD | 1.22% |
| 2012 FY | -19.79 Million USD | -463.96% |
| 2012 Q3 | -3.78 Million USD | 49.24% |
| 2012 Q2 | -7.45 Million USD | -57.84% |
| 2012 Q1 | -4.72 Million USD | -682.45% |
| 2012 Q4 | -3.83 Million USD | -1.29% |
| 2011 FY | -3.51 Million USD | 48.5% |
| 2011 Q2 | -791.36 Thousand USD | 43.88% |
| 2011 Q3 | -2.2 Million USD | -178.8% |
| 2011 Q4 | 810.99 Thousand USD | 136.76% |
| 2011 Q1 | -1.41 Million USD | 39.35% |
| 2010 FY | -6.81 Million USD | -98.24% |
| 2010 Q4 | -2.32 Million USD | -45.73% |
| 2010 Q3 | -1.59 Million USD | 13.05% |
| 2010 Q1 | -1.06 Million USD | 0.31% |
| 2010 Q2 | -1.83 Million USD | -71.8% |
| 2009 Q1 | -890.83 Thousand USD | 81.08% |
| 2009 Q2 | -894.53 Thousand USD | -0.42% |
| 2009 Q4 | -1.07 Million USD | -86.58% |
| 2009 Q3 | -574.22 Thousand USD | 35.81% |
| 2009 FY | -3.43 Million USD | 55.11% |
| 2008 Q3 | -802.96 Thousand USD | 35.76% |
| 2008 Q2 | -1.24 Million USD | -38.99% |
| 2008 Q1 | -899.27 Thousand USD | 16.42% |
| 2008 FY | -7.66 Million USD | -52.06% |
| 2008 Q4 | -4.7 Million USD | -486.4% |
| 2007 Q4 | -1.07 Million USD | 57.64% |
| 2007 FY | -5.03 Million USD | -122.62% |
| 2007 Q1 | -855.93 Thousand USD | -4.86% |
| 2007 Q3 | -2.53 Million USD | -299.95% |
| 2007 Q2 | -635.04 Thousand USD | 25.81% |
| 2006 Q1 | -1.21 Million USD | -42.06% |
| 2006 Q3 | -1.03 Million USD | -230.44% |
| 2006 Q4 | -816.26 Thousand USD | 20.97% |
| 2006 FY | -2.26 Million USD | 65.2% |
| 2006 Q2 | 791.82 Thousand USD | 165.17% |
| 2005 FY | -6.5 Million USD | 20.1% |
| 2005 Q1 | -2.09 Million USD | -14.67% |
| 2005 Q4 | -855.29 Thousand USD | 62.52% |
| 2005 Q3 | -2.28 Million USD | -79.75% |
| 2005 Q2 | -1.26 Million USD | 39.45% |
| 2004 Q1 | -2.45 Million USD | -80.52% |
| 2004 Q4 | -1.82 Million USD | 0.78% |
| 2004 Q3 | -1.84 Million USD | 8.41% |
| 2004 Q2 | -2.01 Million USD | 18.08% |
| 2004 FY | -8.13 Million USD | -97.32% |
| 2003 Q4 | -1.36 Million USD | -38.1% |
| 2003 FY | -4.12 Million USD | -104.51% |
| 2003 Q3 | -985.21 Thousand USD | 10.75% |
| 2003 Q2 | -1.1 Million USD | -63.47% |
| 2003 Q1 | -675.26 Thousand USD | 92.15% |
| 2002 FY | -2.01 Million USD | 90.5% |
| 2002 Q3 | -863.5 Thousand USD | -110.4% |
| 2002 Q4 | -8.59 Million USD | -895.78% |
| 2002 Q2 | 8.3 Million USD | 1067.12% |
| 2002 Q1 | -858.6 Thousand USD | -64.41% |
| 2001 Q2 | -7.98 Million USD | -19.95% |
| 2001 Q4 | -522.22 Thousand USD | 91.39% |
| 2001 Q3 | -6.06 Million USD | 24.09% |
| 2001 Q1 | -6.65 Million USD | 63.94% |
| 2001 FY | -21.22 Million USD | 36.17% |
| 2000 Q3 | -5.03 Million USD | -53.38% |
| 2000 Q2 | -3.28 Million USD | 49.25% |
| 2000 Q1 | -6.47 Million USD | 0.0% |
| 2000 Q4 | -18.46 Million USD | -266.55% |
| 2000 FY | -33.25 Million USD | -437.24% |
| 1999 FY | -6.19 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -137.484% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 54.582% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 105.986% |
| Nascent Biotech, Inc. | -2.08 Million USD | -51.912% |
| Rebus Holdings, Inc. | -1.02 Million USD | -210.925% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 104.869% |
| Qrons Inc. | -789.34 Thousand USD | -301.78% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -401.487% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 94.934% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -663.32% |
| Skye Bioscience, Inc. | -37.64 Million USD | 91.575% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 95.769% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 51.773% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1059.99% |
| SQZ Biotechnologies Company | -79.46 Million USD | 96.009% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -9.647% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -74.204% |
| Mesoblast Limited | -87.95 Million USD | 96.394% |
| Marizyme, Inc. | -65.34 Million USD | 95.147% |
| Genus plc | 7.9 Million USD | 140.145% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 70.882% |
| Pharming Group N.V. | -10.54 Million USD | 69.933% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -46.162% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 14.522% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 64.14% |
| ContraFect Corporation | -65.15 Million USD | 95.132% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 35.092% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -83.59% |
| IMV Inc. | -36.48 Million USD | 91.308% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 60.651% |
| MultiCell Technologies, Inc. | -380.07 USD | -834334.709% |
| ONE Bio Corp. | 8.67 Million USD | 136.552% |
| Accustem Sciences Inc. | -3.74 Million USD | 15.348% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 93.865% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -150.284% |
| Q BioMed Inc. | -2.05 Million USD | -54.546% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 15.043% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -33.205% |
| Biomind Labs Inc. | -1.21 Million USD | -161.17% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 94.69% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -2.246% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 59.871% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -62.7% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -21076.79% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 80.018% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 45.482% |
| GB Sciences, Inc. | -1.36 Million USD | -132.907% |
| Alpha Cognition Inc. | -13.77 Million USD | 76.973% |
| HST Global, Inc. | -146.21 Thousand USD | -2069.097% |
| CSL Limited | 2.64 Billion USD | 100.12% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -80.732% |
| Halberd Corporation | -79.67 Thousand USD | -3880.416% |
| Enzolytics Inc. | -2.17 Million USD | -45.69% |
| Agentix Corp. | -1.37 Million USD | -130.782% |
| Resverlogix Corp. | -3.61 Million USD | 12.149% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.925% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 3336.159% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 145.8% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 20.175% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -4.802% |
| AVAX Technologies, Inc. | -6.41 Million USD | 50.552% |
| Zenith Capital Corp. | -10.59 Million USD | 70.069% |
| Genscript Biotech Corporation | -95.47 Million USD | 96.678% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -13545.28% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 23.505% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -5147.194% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -58.167% |
| Kadimastem Ltd | -3.3 Million USD | 4.111% |
| Helix BioMedix, Inc. | -1.05 Million USD | -200.309% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 16.956% |
| BioStem Technologies, Inc. | -8.48 Million USD | 62.614% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -618.545% |
| LadRx Corporation | 400.44 Thousand USD | 891.982% |
| Cell Source, Inc. | -5.32 Million USD | 40.4% |
| Regen BioPharma, Inc. | 1.02 Million USD | 409.859% |
| Regen BioPharma, Inc. | 1.02 Million USD | 409.859% |
| NovAccess Global Inc. | -4.76 Million USD | 33.502% |
| Affymax, Inc. | -14.42 Million USD | 78.013% |
| Itoco Inc. | -1.86 Million USD | -69.687% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 28.612% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -90.02% |
| Mobile Lads Corp. | -2.26 Million USD | -40.125% |
| CytoDyn Inc. | -49.84 Million USD | 93.637% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -3912.8% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1290.206% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -236.839% |
| SYBLEU INC | -180.3 Thousand USD | -1658.938% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -96.649% |
| International Stem Cell Corporation | -131 Thousand USD | -2320.944% |
| Bioxytran, Inc. | -4.28 Million USD | 25.901% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -5743.595% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -25.341% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 93.403% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -50.021% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -306.133% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -0.108% |
| Neutra Corp. | -233.46 Thousand USD | -1258.42% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 84.37% |
| PureTech Health plc | -65.69 Million USD | 95.173% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 85.087% |
| IXICO plc | -1.17 Million USD | -169.222% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 68.052% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 94.449% |
| CSL Limited | 2.64 Billion USD | 100.12% |
| Cellectis S.A. | -103.17 Million USD | 96.926% |